Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
0J
0J9P.LSE
0J
0J9P.LSE
0J9P.LSE
News
·
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Mkt Cap
N/A
Volume
1.15K
Next Earnings
N/A
Chart
Earnings
News
About
Insider
Filings
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to …
finance.yahoo.com · Apr 22, 2025
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers. Over the next few years, immuno-o…
finance.yahoo.com · Apr 15, 2025
Incyte to Report First Quarter Financial Results
WILMINGTON, Del., April 10, 2025--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 2025. The schedule for the press release and conference call/webca…
finance.yahoo.com · Apr 10, 2025
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del., April 07, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 20,334 shares of the Company’s common stock to 24 new employees. The awards were made under the Company’s 2024 …
finance.yahoo.com · Apr 7, 2025
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY) Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst performers in the im…
finance.yahoo.com · Apr 7, 2025
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. Life and the stock market are both about expectations, and rising above what is expected is…
finance.yahoo.com · Apr 4, 2025
Exploring 3 High Growth Tech Stocks In The US Market
In the last week, the United States market has been flat, but over the past 12 months, it has risen by 8.4%, with earnings expected to grow by 14% per annum in the coming years. In this environment, identifying high-growth tech stocks can be crucial for investors seeking to capit…
finance.yahoo.com · Apr 3, 2025
3 Reasons INCY is Risky and 1 Stock to Buy Instead
Over the past six months, Incyte’s shares (currently trading at $60.02) have posted a disappointing 11.8% loss while the S&P 500 was down 1.7%. This was partly driven by its softer quarterly results and might have investors contemplating their next move. Is there a buying opportu…
finance.yahoo.com · Apr 1, 2025
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
Knight Therapeutics MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialid…
finance.yahoo.com · Mar 26, 2025
1 Healthcare Stock on Our Watchlist and 2 to Brush Off
1 Healthcare Stock on Our Watchlist and 2 to Brush Off From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harme…
finance.yahoo.com · Mar 21, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
0J
0J9P.LSE
0J9P.LSE
Buy
Sell
Market
Limit
Soon
0J9P.LSE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any 0J9P.LSE yet.
Related Tickers
Earnings